These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib? Eskazan AE; Tiribelli M Leuk Res; 2018 Nov; 74():55-56. PubMed ID: 30296661 [No Abstract] [Full Text] [Related]
24. Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients. de Lima LT; Bueno CT; Vivona D; Hirata RD; Hirata MH; Hungria VT; Chiattone CS; Zanichelli MA; Chauffaille Mde L; Guerra-Shinohara EM Hematology; 2015 Apr; 20(3):137-42. PubMed ID: 25056761 [TBL] [Abstract][Full Text] [Related]
25. Treatment Outcomes in CML Patients Treated With Tyrosine Kinase Inhibitors at a Tertiary Teaching Hospital in South Africa. Sissolak G; Badenhorst J; Steenkamp J; Heaney M; Louw V; Schnugh D; Willem P Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):803-10. PubMed ID: 26481837 [TBL] [Abstract][Full Text] [Related]
26. Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function? Vatanmakanian M; Tavallaie M; Ghadami S Cell Commun Signal; 2019 Apr; 17(1):38. PubMed ID: 31014357 [TBL] [Abstract][Full Text] [Related]
27. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia. Lejniece S; Udre I; Rivkina A Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494 [TBL] [Abstract][Full Text] [Related]
29. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia. Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S Cancer Chemother Pharmacol; 2017 Apr; 79(4):737-745. PubMed ID: 28286932 [TBL] [Abstract][Full Text] [Related]
30. Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec. Eskazan AE; Sadri S; Keskin D; Ayer M; Kantarcioglu B; Demirel N; Aydin D; Aydinli F; Yokus O; Ozunal IE; Berk S; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):804-811. PubMed ID: 28847475 [TBL] [Abstract][Full Text] [Related]
31. Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing. Shokeen Y; Sharma NR; Vats A; Taneja V; Minhas S; Jauhri M; Sankaran S; Aggarwal S Ethiop J Health Sci; 2018 Mar; 28(2):135-146. PubMed ID: 29983511 [TBL] [Abstract][Full Text] [Related]
32. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line. Castagnetti F; Di Raimondo F; De Vivo A; Spitaleri A; Gugliotta G; Fabbiano F; Capodanno I; Mannina D; Salvucci M; Antolino A; Marasca R; Musso M; Crugnola M; Impera S; Trabacchi E; Musolino C; Cavazzini F; Mineo G; Tosi P; Tomaselli C; Rizzo M; Siragusa S; Fogli M; Ragionieri R; Zironi A; Soverini S; Martinelli G; Cavo M; Vigneri P; Stagno F; Rosti G; Baccarani M Am J Hematol; 2017 Jan; 92(1):82-87. PubMed ID: 27770583 [TBL] [Abstract][Full Text] [Related]
33. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study. Kizilors A; Crisà E; Lea N; Passera R; Mian S; Anwar J; Best S; Nicolini FE; Ireland R; Aldouri M; Pocock C; Corbett T; Gale R; Bart-Smith E; Weston-Smith S; Wykes C; Kulasekararaj A; Jackson S; Harrington P; McLornan D; Raj K; Pagliuca A; Mufti GJ; de Lavallade H Lancet Haematol; 2019 May; 6(5):e276-e284. PubMed ID: 31036317 [TBL] [Abstract][Full Text] [Related]
34. Single cell sequencing reveals cell populations that predict primary resistance to imatinib in chronic myeloid leukemia. Zhang W; Yang B; Weng L; Li J; Bai J; Wang T; Wang J; Ye J; Jing H; Jiao Y; Chen X; Liu H; Zeng YX Aging (Albany NY); 2020 Nov; 12(24):25337-25355. PubMed ID: 33226961 [TBL] [Abstract][Full Text] [Related]
35. Diagnosis and Treatment of Chronic Myeloid Leukemia in the Imatinib Mesylate Era: Report of the Experience at "La Raza" Medical Center in Mexico. Ayala M; Ávila E; Domínguez J; Aquino X; Vela J Clin Lymphoma Myeloma Leuk; 2016 Feb; 16(2):57-62. PubMed ID: 26699851 [TBL] [Abstract][Full Text] [Related]
38. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. Castagnetti F; Gugliotta G; Breccia M; Iurlo A; Levato L; Albano F; Vigneri P; Abruzzese E; Rossi G; Rupoli S; Cavazzini F; Martino B; Orlandi E; Pregno P; Annunziata M; Usala E; Tiribelli M; Sica S; Bonifacio M; Fava C; Gherlinzoni F; Bocchia M; Soverini S; Bochicchio MT; Cavo M; Giovanni M; Saglio G; Pane F; Baccarani M; Rosti G; Am J Hematol; 2017 Aug; 92(8):797-805. PubMed ID: 28466557 [TBL] [Abstract][Full Text] [Related]
39. Predictive and Prognostic Implications of Variant Philadelphia Translocations in CML: Experience From a Tertiary Oncology Center in Southern India. Kanakasetty GB; Kuntejowdahalli L; Thanky AH; Dasappa L; Jacob LA; Mallekavu SB; Kumari P Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):52-59. PubMed ID: 27743980 [TBL] [Abstract][Full Text] [Related]
40. Association between C1236T Genetic Variant of ABCB1 Gene and Molecular Response to Imatinib in Indonesian Chronic Myeloid Patients. Rinaldi I; Nova R; Widyastuti R; Priambodo R; Instiaty I; Louisa M Asian Pac J Cancer Prev; 2019 Nov; 20(11):3331-3334. PubMed ID: 31759356 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]